Clinical Aspects of Parkinson Disease

Parkinson's Disease: Molecular and Therapeutic Insights From Model Systems

Volumn , Issue , 2008, Pages 1,3-1,8

  Fahn, Stanley ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58549083663     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374028-1.00001-4     Document Type: Chapter

References (8)

1. S. Fahn and J. Jankovic (2007) Principles and Practice of Movement Disorders. Philadelphia: Churchill Livingstone Elsevier This latest textbook devoted to the field of movement disorders contains chapters detailing all the clinical and basic aspects of Parkinson disease. This is an excellent source to obtain additional information about this disease
2. K.R. Chaudhuri, D.G. Healy and A.H. Schapira (2006) Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol 5 235-245. This review article provides a thorough discussion of the nonmotor features occurring in patients with Parkinson disease and also provides a listing of available quantitative rating scales to measure many of these
3. S. Palhagen, E. Heinonen, J. Hagglund, T. Kaugesaar, O. Maki-Ikola and R. Palm (2006) Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66(8), 1200-1206. Apr 25. This article reports the results of a controlled clinical trial over 7 years showing that sustained use of selegiline before and after the addition of levodopa is superior to placebo in the ultimate clinical severity of Parkinson disease, and even requires lower amounts of levodopa to achieve this benefit
4. O. Suchowersky, S. Reich, J. Perlmutter, T. Zesiewicz, G. Gronseth and W.J. Weiner (2006) Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7), 968-975. Apr 11 Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. This Practice Parameter from the American Academy of Neurology provides guidance on distinguishing Parkinson disease (PD) from other forms of parkinsonism. Early falls, poor response to levodopa, symmetry of motor manifestations, lack of tremor, and early autonomic dysfunction are suggestive of these other parkinsonian syndromes
5. R. Pahwa, S.A. Factor, K.E. Lyons, W.G. Ondo, G. Gronseth, H. Bronte-Stewart, M. Hallett, J. Miyasaki, J. Stevens and W.J. Weiner (2006) Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7), 983-995. Apr 11 Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. This Practice Parameter from the American Academy of Neurology provides evidence-based medical and surgical treatment recommendations for patients with Parkinson disease with levodopa-induced motor fluctuations and dyskinesia
6. J.M. Miyasaki, K. Shannon, V. Voon, B. Ravina, G. Kleiner-Fisman, K. Anderson, L.M. Shulman, G. Gronseth and W.J. Weiner (2006) Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7), 996-1002. Apr 11 Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. This Practice Parameter from the American Academy of Neurology provides evidence-based treatment recommendations for patients with Parkinson disease with behavioral and cognitive problems, such as depression, psychosis, and dementia
7. P. Krack, A. Batir, N. Van Blercom, S. Chabardes, V. Fraix, C. Ardouin, A. Koudsie, P.D. Limousin, A. Benazzouz, J.F. LeBas, A.L. Benabid and P. Pollak (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349(20), 1925-1934. Nov 13. This is a report of a 5-year prospective study of the first 49 consecutive patients these investigators treated with bilateral stimulation of the subthalamic nucleus. Compared with base line, the patients’ motor function (excluding speech which did not improve) while off medication improved by 54%. However, the disease progressed as reflected by a worsening of akinesia, speech, postural stability, and freezing of gait scores while on-medication over the 5 years. The dose of dopaminergic treatment and the duration and severity of levodopa-induced dyskinesia were reduced
8. G. Deuschl, C. Schade-Brittinger, P. Krack, J. Volkmann, H. Schäfer, K. Bötzel, C. Daniels, A. Deutschländer, U. Dillmann, W. Eisner, D. Gruber, W. Hamel, J. Herzog, R. Hilker, S. Klebe, M. Kloss, J. Koy, M. Krause, A. Kupsch, D. Lorenz, S. Lorenzl, H.M. Mehdorn, J.R. Moringlane, W. Oertel, M.O. Pinsker, H. Reichmann, A. Reuss, G.H. Schneider, A. Schnitzler, U. Steude, V. Sturm, L. Timmermann, V. Tronnier, T. Trottenberg, L. Wojtecki, E. Wolf, W. Poewe and J. Voges (2006) German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355(9), 896-908. Aug 31 This is a report of an unblinded randomized-pairs trial, comparing changes from baseline to 6 months in the quality of life and the severity of motor symptoms without medication in patients with advanced Parkinson disease undergoing stimulation of the subthalamic nucleus or medical treatment. Neurostimulation resulted in improved quality of life and motor scores (without medication). There was also a lower dose of dopaminergic medication with less dyskinesia. Serious adverse events were more common with neurostimulation than with medication alone